ArticleFrontiers in allergy2025
Dietary 3'-sialyllactose reduces sensitization and type 2 inflammation in a house dust mite induced acute allergic asthma model.
Article in Frontiers in allergy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Allergic asthma affects over 300 million people globally, characterized by a type 2 immune response to allergens like house dust mite (HDM). This includes eosinophilia, IgE production, and symptoms such as bronchial hyperresponsiveness. Human milk oligosaccharides (HMOS), ingested by breastfed infants, have immunomodulatory effects and may help prevent allergic diseases, like asthma. Methods: This study investigates the effects of two sialylated HMOS, 3'-sialyllactose (3'SL) and 6'-sialyllactose (6'SL), in a murine model of HDM-induced allergic asthma. Male BALB/c mice (6-7 weeks old) were fed an AIN93G diet with or without 0.1% or 0.5% 3'SL or 6'SL from 2 weeks before HDM sensitization until sacrifice. Airway hyperresponsiveness was measured after the final HDM challenge, and broncho-alveolar lavage fluid (BALF) and lung tissue were collected for analysis. Results: Dietary 0.5% 3'SL, 0.1% 6'SL, or 0.5% 6'SL prevented methacholine-induced airway hyperresponsiveness in HDM-challenged mice compared to control diet. Mice fed the 0.5% 3'SL diet had elevated SCFA levels in cecum content. Both 3'SL and 6'SL groups showed reduced HDM-induced macrophage influx in BALF. Mice on 3'SL diets had lower total inflammatory cell influx, while those on 0.5% 6'SL had increased eosinophils in BALF, associated with higher IL33, TNFα, CCL5, IFNγ levels, and reduced regulatory T cells. The 3'SL diets also prevented increases in HDM-specific IgE and mMCP1 in serum. Conclusion: Dietary 3'SL and 6'SL showed dose-dependent, differential clinical and immunological outcomes in HDM-sensitized mice. Both 0.5% 3'SL, 0.1% 6'SL, and 0.5% 6'SL reduced airway hyperresponsiveness. However, 0.5% 6'SL increased eosinophilic inflammation, while 3'SL protected against HDM-induced sensitization and asthma development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.